Advances in Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. CLL has a highly varied clinical course. While advances in CLL therapy are noted, many patients still succumb to this illness. Like most progress in medicine, solid
- PDF / 4,212,381 Bytes
- 337 Pages / 439.42 x 683.15 pts Page_size
- 39 Downloads / 183 Views
Sami Malek Editor
Advances in Chronic Lymphocytic Leukemia
Advances in Experimental Medicine and Biology Editorial Board: IRUN R. COHEN, The Weizmann Institute of Science, Rehovot, Israel ABEL LAJTHA, N.S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA JOHN D. LAMBRIS, University of Pennsylvania, Philadelphia, PA, USA RODOLFO PAOLETTI, University of Milan, Milan, Italy –––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
For further volumes: http://www.springer.com/series/5584
Sami Malek Editor
Advances in Chronic Lymphocytic Leukemia
Editor Sami Malek Department of Internal Medicine University of Michigan Ann Arbor, MI, USA
ISSN 0065-2598 ISBN 978-1-4614-8050-1 ISBN 978-1-4614-8051-8 (eBook) DOI 10.1007/978-1-4614-8051-8 Springer New York Heidelberg Dordrecht London Library of Congress Control Number: 2013944908 # Springer Science+Business Media New York 2013 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
Preface
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world but is rare in Asia. CLL has a highly varied clinical course. While advances in CLL therapy are noted, many patients still succumb to this illness. To date, most CLL patients are diagnosed in early stages and are not in need of im
Data Loading...
